FENC (Fennec Pharmaceuticals) Total Inventories : $1.13 Mil (As of Sep. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Total Inventories?

Fennec Pharmaceuticals's total inventories for the quarter that ended in Sep. 2024 was $1.13 Mil. Fennec Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $1.63 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Fennec Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-0.49.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Fennec Pharmaceuticals's Days Inventory for the three months ended in Sep. 2024 was 109.91.

Inventory Turnover measures how fast the company turns over its inventory within a year. Fennec Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.83.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Fennec Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.23.

Fennec Pharmaceuticals Total Inventories Historical Data

The historical data trend for Fennec Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Total Inventories Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

0.58

2.16

1.06

Fennec Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Inventories	Get a 7-Day Free Trial															2.16	2.06	2.14	1.13	1.06

Fennec Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Fennec Pharmaceuticals (NAS:FENC) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Fennec Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

	Net-Net Working Capital Per Share (Q: Sep. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(40.32	+	0.75 * 12.908	+	0.5 * 1.125	-	64.092
-	0	-	0)	/	27.422
=	-0.49

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Fennec Pharmaceuticals's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	1.6345	/	1.357	*	365 / 4
	=	109.91

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Fennec Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2024 )	/	Average Total Inventories (Q: Sep. 2024 )
	=	1.357	/	1.6345
	=	0.83

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Fennec Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	1.6345	/	6.974
	=	0.23

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Fennec Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Executives

Chris A Rallis	director	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Rosty Raykov	director, officer: Chief Executive Officer	C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Adrian Haigh	director	83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Robert Andrade	officer: Chief Financial Officer	C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Marco Maria Brughera	director	VIALE STEFINI 14, MILANO L6 00000
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel	officer: Chief Commercial Officer	1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp	10 percent owner	1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook	director	PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza	10 percent owner	VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040